Comparison of live attenuated and inactivated influenza vaccines in cystic fibrosis patients and their families: Results of a 3-year study

Journal of Infectious Diseases

Volumn 169, Issue 2, 1994, Pages 241-247

  Gruber, William C ^a   Campbell, Preston W ^a   Thompson, Juliette M ^a   Reed, George W ^a   Roberts, Barbara ^a   Wright, Peter F ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INACTIVATED VACCINE; INFLUENZA VACCINE; LIVE VACCINE;

ADOLESCENT; ADULT; ANTIBODY PRODUCTION; ARTICLE; CHILD; CHILL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; CYSTIC FIBROSIS; DRUG SAFETY; ERYTHEMA; FEVER; HUMAN; INFANT; INFLUENZA VACCINATION; INTRAMUSCULAR DRUG ADMINISTRATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; SORE THROAT; VIRUS INFECTION;

ADOLESCENT; ADULT; ANTIBODIES, VIRAL; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; DOUBLE-BLIND METHOD; HUMANS; INFANT; INFLUENZA A VIRUS; INFLUENZA VACCINES; INFLUENZA, HUMAN; MIDDLE AGED; VACCINES, ATTENUATED;

EID: 0028032048     PISSN: 00221899     EISSN: 15376613     Source Type: Journal    
DOI: 10.1093/infdis/169.2.241     Document Type: Article

References (38)

1. Frank AL, Taber LH, Wells JM. Comparison of infection rates and severity of illness for influenza A subtypes H IN 1 andH3N2.J Infect Dis 1985;151:73-80.
2. Kim HW, Brandt CD. Arrabio JO, Murphy B, Chanock RM, Parrott RH. Influenza A and B virus infection in infants and young children during the years 1957-1976. Am J Epidemiol 1979;109:464-79.
3. Centers for Disease Control. Prevention and control of influenza: Recommendations of the Immunization Practices Advisory Committee. MMWR 1992;41 (RR-9): 1 — 15.
4. Glezen WP. The pediatrician's role in influenza control. Pediatr Infect Dis 1986;5:615-8.
5. Wright PF, Khaw KT, Oxman MT, Schwachman H. Evaluation of the safety of amantadine HCL and the role of respiratory viral infections in children with cystic fibrosis. J Infect Dis 1976;134:144-9.
6. Wang EEL, Prober CG. Manson B, Corey M, Levison H. Association of respiratory viral infections with pulmonary deterioration in patients with cystic fibrosis. N Engl J Med 1984;311:1653-8.
7. Pribble CG. Black PG, Bosso JD. Turner RB. Clinical manifestations of exacerbations of cystic fibrosis associated with non-bacterial infections. J Pediatr 1990; 117:200-4.
8. Ferson MJ, Morton JR, Robertson PW. Impact ofinfluenza on morbidity in children with cystic fibrosis. J Paediatr Child Health 1991; 27:308-11.
9. Modlin JF, Smith DH, Harding L. Clinical trials of bivalent A/New Jersey/76-A/Victoria/75 influenza vaccines in high-risk children. J Infect Dis 1977; 136(suppl):S626—31.
10. Hilman BC, Jamison RM. Kirkpatrick CJ. Reactivity and antibody response to vaccination with bivalent influenza A/Victoria/75-A/New Jersey/76 vaccines in children with chronic pulmonary diseases. J Infect Dis 1977;136(suppl):S638-44.
11. Hall CB, Hahng L, Alexson C, Meagher P, Manning JA. Trial of biva-lent influenza A vaccine in high risk infants. J Infect Dis 1977; l36(suppl):S648-51.
12. Allison JE, Glezen WP, Taber LH, Paredes A, Webster RG. Reacto-genicity and immunogenicity of bivalent influenza A and monovalent influenza B virus vaccines in high risk children. J Infect Dis 1977; l36(suppl):S672-6.
13. King JC Jr. Gross PA. Denning CR. Gaerlan PF, Wright PF, Quinnan GV Jr. Comparison of live and inactivated influenza vaccine in high risk children. Vaccine 1987;5:234-8.
14. Maassab HF. Adaptation in growth characteristics of influenza virus at 25°C. Nature 1967;213:612-4.
15. Maassab HF, Kendal AP, Abrams GD, Monto AS. Evaluation of a cold-recombinant influenza virus vaccine in ferrets. J Infect Dis 1982;146:780-90.
16. Cox NF. Maassab HF, Kendal AP. Comparative studies of wild-type and cold mutant (temperature-sensitive) influenza viruses: Nonrandom reassortment of genes during preparation of live virus vaccine candidates by recombination at 25°C between recent H3N2 and H1N1 epidemic strain and cold-adapted A/Ann Arbor/6/60. Virology 1979;97:190-4.
17. Davenport FM, Hennessy AV, Maassab HF, et al. Pilot studies on recombinant cold-adapted live type A and B influenza virus vaccines. J Infect Dis 1977;136:17-25.
18. Wright PF, Sell SH, Shinozaki T, Thompson J. Karzon DT. Safety and antigenicity of influenza A/Hong Kong/68 ts-1 [E] (H3N2) vaccine in young seronegative children. J Pediatr 1975:87; 1109-16.
19. Wright PF, Okabe N, McKee KT, Maassab HF, Karzon DT. Cold-adapted recombinant influenza A virus vaccines in seronegative young children. J Infect Dis 1982;146:71-9.
20. Wright PF, Karzon DT. Live attenuated influenza vaccines. Prog Med Virol 1987;34:70-88.
21. Clements ML. Betts RF. Murphy BR. Advantage of live attenuated cold-adapted influenza A virus over inactivated vaccine for A/Washington/80 (H3N2) wild-type virus infection. Lancet 1984;2:705-8.
22. Clements ML, Tierney EL, Murphy BR. Response of seronegative and seropositive adult volunteers to live attenuated cold-adapted reassortant influenza A virus vaccine. J Clin Microbiol 1985;21:997-9.
23. Feldman S, Wright PF. Webster RG, et al. Use of influenza A virus vaccines in seronegative children: Live cold-adapted versus inactivated whole virus. J Infect Dis 1985; 152:1212-8.
24. Johnson PR, Feldman S, Thompson JM, Mahoney JD. Wright PF. Immunity to influenza A virus infection in young children: A comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis 1986;154:121-7.
25. Clements ML. Snyder MH, Sears SD. Maassab HF, Murphy BR. Evaluation of the infectivity, immunogenicity, and efficacy of live cold-adapted influenza B/Ann Arbor/86 reassortment virus vaccine in adult volunteers. J Infect Dis 1990;161:869-77.
26. Edwards KM, King JC. Steinhoff MC, et al. Safety and immunogenicity of live attenuated cold-adapted influenza B/Ann Arbor/1/86 reassortant virus vaccine in infants and children. J Infect Dis 1991; 163:740-5.
27. Belshe TB, Swierkosz EM, Anderson EL, Newman FK, Nugent SL, Maassab HF. Immunization of infants and young children with live attenuated trivalent cold-recombinant influenza A HIN1, H3N2, and B vaccine. J Infect Dis 1992;165:727-32.
28. Keitel WA, Couch RB, Quarles JM, Cate TR, Baxter B, Maassab HF. Trivalent attenuated cold-adapted influenza virus vaccine: Reduced viral shedding and serum antibody responses in susceptible adults. J Infect Dis 1993;167:305-11.
29. Gruber WC, Kirschner K, Tollefson S, et al. Comparison of monovalent and trivalent live attenuated influenza vaccines in young children. J Infect Dis 1993;168:53-60.
30. Belshe RB, Van Voris LP. Cold-recombinant influenza A/California/10/78 (HI Nl) virus vaccine (CR-37) in seronegative children: Infectivity and efficacy against investigational challenge. J Infect Dis 1984;149:735-40.
31. Clover RD, Crawford S, Glezen WP, Taber LH, Matson CC. Couch RB. Comparison of heterotypic protection against influenza A/Taiwan/86 (H 1NI) by attenuated and inactivated vaccines to A/Chile/83-like viruses. J Infect Dis 1991;163:300-4.
32. Edwards KM, Dupont WD, Wright PF. Efficacy of live attenuated influenza vaccine [abstract 1292], In: Program and abstracts of the 31st Interscience Conference on Antimicrobial Agents and Chemotherapy (Chicago). Washington, DC: American Society for Microbiology, 1987.
33. Groothuis JR, Levin MJ. RabalaisGP, Meiklejohn G, Lauer BA. Immunization of high-risk infants younger than 18 months of age with split-product influenza vaccine. Pediatrics 1991;87:823-8.
34. Chapman LE, Tipple MA. Schmeltz LM, et al. Influenza—United States, 1989-90 and 1990-91 seasons. MMWR 1992;41 (SS-3):35-46.
35. Couch RB, Webster RG, Kasel JA. Cate TR. Efficacy of purified subunit vaccines and relation to the major antigenic determinants on the hemagglutinin molecule. J Infect Dis 1979;140:553-9.
36. Gross PA. Denning CR, Pureza FG, et al. Benefit of annual influenza immunization in patients with cystic fibrosis. In: Hahnoun C, Kendal AP. Klenk AD, Ruben FL, eds. Options for the control of influenza II. Amsterdam: Excerpta Medica, 1993.
37. Fedson DS. Influenza prevention and control. Past practices and future prospects. Am J Med 1987;82:42-7.
38. Gruber WC, Hinson HP, Holland KL, Thompson JM, Reed GW, Wright PF. Comparative trial of large-particle aerosol and nose drop administration of live attenuated influenza vaccines. J Infect Dis 1993;168:1282-5.